These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review. Duarte Lau F; Giugliano RP JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218 [TBL] [Abstract][Full Text] [Related]
13. Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice. Yenilmez B; Kelly M; Zhang GF; Wetoska N; Ilkayeva OR; Min K; Rowland L; DiMarzio C; He W; Raymond N; Lifshitz L; Pan M; Han X; Xie J; Friedline RH; Kim JK; Gao G; Herman MA; Newgard CB; Czech MP J Biol Chem; 2022 Oct; 298(10):102401. PubMed ID: 35988648 [TBL] [Abstract][Full Text] [Related]
14. ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. Sanjay KV; Vishwakarma S; Zope BR; Mane VS; Mohire S; Dhakshinamoorthy S Curr Res Pharmacol Drug Discov; 2021; 2():100051. PubMed ID: 34909677 [TBL] [Abstract][Full Text] [Related]
15. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis. Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055 [TBL] [Abstract][Full Text] [Related]
16. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205 [TBL] [Abstract][Full Text] [Related]
17. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596 [TBL] [Abstract][Full Text] [Related]
18. Mendelian Randomization Study of Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797 [TBL] [Abstract][Full Text] [Related]
19. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis. Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265 [TBL] [Abstract][Full Text] [Related]
20. In Steatotic Cells, ATP-Citrate Lyase mRNA Is Efficiently Translated through a Cap-Independent Mechanism, Contributing to the Stimulation of De Novo Lipogenesis. Siculella L; Giannotti L; Testini M; Gnoni GV; Damiano F Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]